DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with improvements in exploratory cardiac endpoints relative to external placebo, including levels of NT-proBNP, a measure of cardiac stress, and a trend towards improvement in echocardiographic parameters.
Consistent beneficial effects on cardiac measures were observed in the modified intent-to-treat (mITT) group. Additionally, in a planned cohort of patients from the mITT population, vutrisiran treatment reduced cardiac uptake of technetium on scintigraphy imaging relative to baseline in a majority of assessable patients, including those with Perugini grade >=2 at baseline, suggesting that patients with the highest degrees of cardiac amyloid burden may recognize benefit from a TTR silencer.
videos & visualsISA 2020 | Burning Questions: ASCT in AL Amyloidosishttps://www.youtube.com/watch?v=KmcLvnXC...
educationAmyloidosis and the Heart: Patient InformationIn some patients with amyloidosis there ...
people & placesThe Canadian Amyloidosis Support Network, Inc.The Canadian Amyloidosis Support Network...
videos & visualsIonis Clinical Trial Update – ASG Webinar 6/11https://www.youtube.com/watch?v=K2TmwAfu...
videos & visualsMatt Millen Needed a Heart Transplanthttps://vimeo.com/320786758...
videos & visualsFinancial Assistance Update: Paula Schmitt – ASG Webinar 5/13https://www.youtube.com/watch?v=NrEjyVeJ...
videos & visualsISA 2020 | MRD Using Multi-Parametric Flow Cytometry in AL Amyloidosishttps://www.youtube.com/watch?v=hhOs8uTf...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.